Aa Lettergrootte
16
  • About Lareb
  • Search information about ADRs
  • Subscribe to newsletter
Updates
  • Potential liver toxicity of herbal supplement NMDA relief Exendo®
    The Netherlands Pharmacovigilance Centre Lareb received two reports of liver toxicity associated with the use of herbal supplement NMDA relief Exendo®. One patient needed a liver t ...
    Read more
    31 JUL
  • First results of Dutch Biologic Monitor
    48% of patients experienced at least one adverse drug reaction (ADR) after administration of a biological drug. ADRs most often reported were injection site reactions, followed by ...
    Read more
    25 JUL
  • Overview reports on Meningococcal group ACWY vaccine (Nimenrix®)
    Since May 1st, 2018, all children aged 14 months in the Netherlands are vaccinated against Meningococcal type ACWY with the vaccine Nimenrix®. The Netherlands Pharmacovigilance Cen ...
    Read more
    24 JUL
  • ConcePTION project has been launched
    Today, only about 5% of medications have adequate safety information on use in pregnant or breastfeeding women. Obtaining reliable safety information can take 20 or more years to c ...
    Read more
    02 JUL
  • Hair loss associated with use tioguanine (Thiosix®) for inflammatory bowel disease
    Over the last five years, the Netherlands Pharmacovigilance Centre Lareb received twenty reports of hair loss by women associated with the use of tioguanine for bowel disease. For ...
    Read more
    26 JUN
  • More adverse drug reactions are reported for women
    Women have a higher risk of adverse drug reactions (ADRs) being reported than men, even when differences in the number of drug users is taken into account. Lareb investigated this ...
    Read more
    26 JUN